{
    "root": "31165a2d-8d36-594f-e063-6394a90a9669",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "AMOXICILLIN AND CLAVULANATE POTASSIUM",
    "value": "20250324",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "ETHYLCELLULOSE (10 MPA.S)",
            "code": "3DYK7UYZ62"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "AMOXICILLIN",
            "code": "804826J2HU"
        },
        {
            "name": "CLAVULANATE POTASSIUM",
            "code": "Q42OMW3AT8"
        }
    ],
    "indications": "amoxicillin clavulanate potassium tablets indicated treatment infections adults pediatric patients , due susceptible isolates designated bacteria conditions listed : \u2022 lower respiratory tract infections- caused beta\u2011lactamase\u2011producing isolates haemophilus influenzaeand moraxella catarrhalis . \u2022 acute bacterial otitis media- caused beta\u2011lactamase\u2011producing isolates h. influenzaeand m. catarrhalis . \u2022 sinusitis- caused beta\u2011lactamase\u2011producing isolates h. influenzaeand m. catarrhalis . \u2022 skin skin structure infections- caused beta\u2011lactamase\u2011producing isolates staphylococcus aureus , escherichia coli , klebsiellaspecies . \u2022 urinary tract infections- caused beta\u2011lactamase\u2011producing isolates e. coli , klebsiellaspecies , enterobacterspecies . limitations susceptibility test results show susceptibility amoxicillin , indicating beta-lactamase production , amoxicillin clavulanate potassium tablets used . usage reduce development drug\u2011resistant bacteria maintain effectiveness amoxicillin clavulanate potassium tablets antibacterial drugs , amoxicillin clavulanate potassium tablets used treat prevent infections proven strongly suspected caused susceptible bacteria . culture susceptibility information available , considered selecting modifying antibacterial therapy . absence data , local epidemiology susceptibility patterns may contribute empiric selection therapy .",
    "contraindications": "adults pediatric patients greater 40 kg : 500 875 mg every 12 hours 250 500 mg every 8 hours , based amoxicillin component . ( 2.2 , 2.3 ) pediatric patients aged 12 weeks ( 3 months ) older : 25 45 mg/kg/day every 12 hours 20 40 mg/kg/day every 8 hours , adult dose . ( 2.3 ) neonates infants less 12 weeks age : 30 mg/kg/day divided every 12 hours , based amoxicillin component . 125 mg/5 ml oral suspension recommended . ( 2.3 )",
    "warningsAndPrecautions": "amoxicillin clavulanate potassium tablets , usp : 500 mg/125 mg tablets : white off-white colored , capsule shaped , biconvex , film-coated tablets debossed \u201c 06 \u201d one side plain side . tablet contains 500 mg amoxicillin trihydrate 125 mg clavulanic acid potassium salt ( equivalent 149 mg clavulanate potassium ) . ndc : 70518-2625-00 ndc : 70518-2625-01 ndc : 70518-2625-02 ndc : 70518-2625-03 ndc : 70518-2625-04 ndc : 70518-2625-05 packaging ; 30 1 blister pack packaging : 20 1 bottle plastic packaging : 14 1 bottle plastic packaging : 20 1 bottle plastic packaging : 30 1 blister pack packaging : 14 1 bottle plastic store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . dispense original container . advise patients keep closed container . keep reach children . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "history serious hypersensitivity reaction ( e.g . , anaphylaxis stevens-johnson syndrome ) amoxicillin clavulanate potassium beta\u2011lactams ( e.g . , penicillins cephalosporins ) . ( 4.1 ) history cholestatic jaundice/hepatic dysfunction associated amoxicillin clavulanate potassium . ( 4.2 )",
    "indications_original": "Amoxicillin and clavulanate potassium tablets are indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below:\n                  \u2022\n \n  Lower Respiratory Tract Infections- caused by beta\u2011lactamase\u2011producing isolates of\n \n  Haemophilus influenzaeand\n \n  Moraxella catarrhalis. \n    \u2022\n \n  Acute Bacterial Otitis Media- caused by beta\u2011lactamase\u2011producing isolates of\n \n  H. influenzaeand\n \n  M. catarrhalis. \n    \u2022\n \n  Sinusitis- caused by beta\u2011lactamase\u2011producing isolates of\n \n  H. influenzaeand\n \n  M. catarrhalis. \n    \u2022\n \n  Skin and Skin Structure Infections- caused by beta\u2011lactamase\u2011producing isolates of\n \n  Staphylococcus aureus, Escherichia coli,and\n \n  Klebsiellaspecies. \n    \u2022\n \n  Urinary Tract Infections- caused by beta\u2011lactamase\u2011producing isolates of\n \n  E. coli, Klebsiellaspecies,\n \n  and\n \n  Enterobacterspecies. \n  \n                     Limitations of Use\n                       When susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, amoxicillin and clavulanate potassium tablets should not be used. \n  \n                     Usage\n                       To reduce the development of drug\u2011resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium tablets and other antibacterial drugs, amoxicillin and clavulanate potassium tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",
    "contraindications_original": "Adults and Pediatric Patients greater than 40 kg: 500 or 875 mg every 12 hours or 250 or 500 mg every 8 hours, based on amoxicillin component. ( 2.2 , 2.3 ) Pediatric patients aged 12 weeks (3 months) and older: 25 to 45 mg/kg/day every 12 hours or 20 to 40 mg/kg/day every 8 hours, up to the adult dose. ( 2.3 ) Neonates and infants less than 12 weeks of age: 30 mg/kg/day divided every 12 hours, based on the amoxicillin component. Use of the 125 mg/5 mL oral suspension is recommended. ( 2.3 )",
    "warningsAndPrecautions_original": "Amoxicillin and Clavulanate Potassium Tablets, USP:\n                  500 mg/125 mg Tablets:\u00a0 White to off-white colored, capsule shaped, biconvex, film-coated tablets debossed with \u201cI 06\u201d on one side and plain on the other side. Each tablet contains 500 mg of amoxicillin as the trihydrate and 125 mg of clavulanic acid as the potassium salt (equivalent to 149 mg of clavulanate potassium).\n                  \n                  NDC: 70518-2625-00\n                  NDC: 70518-2625-01\n                  NDC: 70518-2625-02\n                  NDC: 70518-2625-03\n                  NDC: 70518-2625-04\n                  NDC: 70518-2625-05\n                  PACKAGING; 30 in 1 BLISTER PACK\n                  PACKAGING: 20 in 1 BOTTLE PLASTIC\n                  PACKAGING: 14 in 1 BOTTLE PLASTIC\n                  PACKAGING: 20 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 14 in 1 BOTTLE PLASTIC\n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature]. Dispense in original container. Advise patients to keep in closed container.\n                  \n                  Keep out of the reach of children.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin and clavulanate potassium or to other beta\u2011lactams (e.g., penicillins or cephalosporins). ( 4.1 ) History of cholestatic jaundice/hepatic dysfunction associated with amoxicillin and clavulanate potassium. ( 4.2 )"
}